Denver, Colorado - As the final hour of trading unfolds, momentum is clustering around breakthrough science, regulatory catalysts, strategic commodities, and headline M&A. Here are the stocks commanding attention into the close and potentially into afterhours.
Materials Disruption: Kraig Biocraft Presses Highs
Kraig Biocraft Laboratories (OTCQB:KBLB) is pushing toward 52-week highs after landing on the cover of National Geographic’s March 2026 issue, spotlighting its recombinant spider silk platform.
The publication detailed Kraig’s genetically engineered silkworms, which produce spider silk fibers through their natural biological process, a key distinction from synthetic approaches. Demonstrations highlighted towing a car and suspending a person using a lightweight silk loop, reinforcing the fiber’s strength-to-weight advantage.
What’s driving Power Hour interest is timing. The company is preparing to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, targeting up to 10 metric tons per month of cocoons beginning in March. If sustained, Kraig could become only the second company to achieve commercial-scale output from a transgenic animal platform, historically associated with ATryn, later incorporated into Sanofi (NASDAQ:SNY) after Genzyme’s acquisition.
The narrative is shifting from proof-of-concept to production scale. Investors appear focused on confirmation of initial deliveries to previously disclosed global brand partners spanning luxury fashion and performance apparel.
Signing Day Sports Attempting to Knock Out Another Pivot Point
Signing Day Sports (NYSE:SGN) continues its January rally, clearing technical resistance near $0.60 as traders eye the next pivot level at around 95-cents.
FDA Catalyst: Allurion Targets 80 Million Americans
Healthcare traders are also monitoring Allurion Technologies (NYSE:ALUR) after the U.S. FDA approved the company’s Allurion Gastric Balloon System featuring the Allurion Smart Capsule.
CEO Dr. Shantanu Gaur called it “a watershed moment…for obesity care in the United States,” highlighting the system’s positioning as a non-surgical, non-GLP-1 alternative. The capsule is swallowed in a 15-minute office visit and remains in the stomach for approximately four months before naturally passing.
With roughly 80 million Americans falling within the approved BMI range, the addressable market is substantial. Outside the U.S., more than 200,000 patients have been treated, with reported total body weight loss of 14% in commercial settings and over 20% with two treatment cycles.
As GLP-1 discontinuation rates remain a topic of industry discussion, ALUR enters the close as a regulatory winner with a clearly defined commercialization pathway.
Rare Earth Strength: Critical Metals Advances Tanbreez
Strategic minerals remain in focus with Critical Metals Corp. (NASDAQ:CRML) continuing its move higher following last week’s release of strong re-assay results from 33 drill holes at the Hill Deposit within its Tanbreez Heavy Rare Earth project in Greenland.
Highlights included grades up to 0.94% TREO and a weighted average TREO+Y of 0.44%, with approximately 24% heavy rare earth oxide content. CEO Tony Sage said the results “confirm TREO grades within a tight 2–5% precision range,” underscoring data robustness.
With global demand for heavy rare earths tied to EVs, defense systems, and advanced magnets, CRML is positioning Tanbreez as a potential cornerstone Western supply source. Power Hour traders appear to be leaning into the geopolitical and strategic mineral angle as drilling plans advance toward 2026.
Big Biotech M&A: Gilead Makes Its Move
Large-cap biotech consolidation is back in the spotlight.
Gilead Sciences (NASDAQ:GILD) announced a definitive agreement to acquire Arcellx (NASDAQ:ACLX) for $115 per share in cash plus a $5 contingent value right tied to milestones, implying an equity value of approximately $7.8 billion.
The acquisition gives Gilead full control of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma. The FDA has accepted the BLA, with a PDUFA date of December 23, 2026.
Gilead CEO Daniel O’Day said anito-cel “could become a foundational treatment for multiple myeloma over time,” signaling long-term oncology ambition. The deal consolidates economics from a prior collaboration and reinforces that validated cell therapy platforms with regulatory traction remain premium assets.
Watch for afterhours commentary from analysts digesting synergy implications and pipeline expansion.
Conference Spotlight: Vor Bio on Deck
Vor Bio (NASDAQ:VOR) is drawing incremental attention ahead of its presentation at the TD Cowen Health Care Conference in Boston. Investor conference appearances can catalyze volatility, particularly for clinical-stage biotech names navigating pipeline positioning and financing outlooks.
With sector-wide M&A heating up, small- and mid-cap immunotherapy players remain firmly on watch lists.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
CONTACT:
24/7 Market News
Editor@247marketnews.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.